查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1703464

安德森-塔維爾症候群市場－全球產業規模、佔有率、趨勢、機會和預測，按疾病類型、配銷通路、地區和競爭細分，2020-2030 年

Andersen-Tawil Syndrome Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Disease Type, By Distribution Channel, By Region and Competition, 2020-2030F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

2024 年全球安德森-塔維爾症候群 (ATS) 市場價值為 226 萬美元，預計到 2030 年將達到 349 萬美元，預測期內的年複合成長率(CAGR) 為 7.47%。

市場概覽
預測期 2026-2030
2024年市場規模 226萬美元
2030年市場規模 349萬美元
2025-2030 年複合年成長率 7.47%
成長最快的領域 網路藥局
最大的市場 北美洲

人們對罕見遺傳疾病的認知不斷提高，加上診斷技術的進步，推動了人們對 ATS 市場的興趣。安德森-塔維爾症候群是一種罕見的遺傳性離子通道疾病，會影響骨骼肌、心臟功能和身體發育，常導致週期性麻痺和危及生命的心律不整。醫療保健專業人員的認知不斷提高以及基因檢測方法的改進使得早期診斷成為可能，這對於及時有效的疾病管理至關重要。

精準醫療和個人化治療策略的出現正在進一步影響ATS標靶治療的發展。儘管目前的治療選擇仍然有限，但對鉀通道調節劑和基因療法的持續研究具有巨大的前景。製藥公司和研究機構加大對 ATS 患者未滿足需求的投資也促進了市場的成長。

關鍵市場促進因素

基因診斷的進展

主要市場挑戰

症狀複雜導致診斷延遲

對於涉及心臟併發症的病例，這些延誤尤其有害，因為及時干預對於防止嚴重後果至關重要。

主要市場趨勢

尖端基因診斷和個人化護理

目錄

第 1 章：產品概述

第2章：研究方法

第3章：執行摘要

第 4 章：全球安德森-塔維爾症候群市場展望

  • 市場規模和預測
    • 按價值
  • 市場佔有率和預測
    • 依疾病類型（1 型、2 型）
    • 按配銷通路（醫院藥房、零售藥房、網路藥房）
    • 按地區
    • 按公司分類（2024）
  • 市場地圖
    • 依疾病類型
    • 按配銷通路
    • 按地區

第5章：亞太地區安德森-塔維爾症候群市場展望

  • 市場規模和預測
    • 按價值
  • 市場佔有率和預測
    • 依疾病類型
    • 按配銷通路
    • 按國家/地區
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 澳洲
    • 日本
    • 韓國

第6章：歐洲安德森-塔維爾症候群市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 歐洲：國家分析
    • 法國
    • 德國
    • 西班牙
    • 義大利
    • 英國

第7章：北美安德森-塔維爾症候群市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 北美：國家分析
    • 美國
    • 墨西哥
    • 加拿大

第8章：南美安德森-塔維爾症候群市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 南美洲：國家分析
    • 巴西
    • 阿根廷
    • 哥倫比亞

第9章：中東和非洲安德森-塔維爾症候群市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • MEA：國家分析
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國

第10章：市場動態

  • 驅動程式
  • 挑戰

第 11 章：市場趨勢與發展

  • 最新動態
  • 產品發布
  • 併購

第 12 章：全球安德森-塔維爾症候群市場：SWOT 分析

第 13 章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的力量
  • 顧客的力量
  • 替代產品的威脅

第 14 章：競爭格局

  • Merck KGA.
  • Grevis Pharmaceuticals
  • Xeris Pharma
  • Novartis AG
  • Advanz Pharmaceuticals
  • Alembic Pharmaceuticals
  • Avet Pharmaceuticals
  • Hikma Pharmaceuticals
  • Micro Labs
  • Advagen Pharma

第 15 章：策略建議

第16章調查會社について,免責事項

簡介目錄
Product Code: 16864

Global Andersen-Tawil Syndrome (ATS) market was valued at USD 2.26 million in 2024 and is projected to reach USD 3.49 million by 2030, growing at a compound annual growth rate (CAGR) of 7.47% during the forecast period.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 2.26 Million
Market Size 2030USD 3.49 Million
CAGR 2025-20307.47%
Fastest Growing SegmentOnline Pharmacies
Largest MarketNorth America

Rising awareness of rare genetic disorders, coupled with advancements in diagnostic technologies, is propelling interest in the ATS market. Andersen-Tawil Syndrome is a rare genetic channelopathy that impacts skeletal muscles, cardiac function, and physical development, often resulting in periodic paralysis and life-threatening arrhythmias. Increased recognition among healthcare professionals and improvements in genetic testing methodologies are enabling earlier diagnosis, which is critical for timely and effective disease management.

The emergence of precision medicine and personalized therapeutic strategies is further influencing the development of targeted treatments for ATS. Although current treatment options remain limited, ongoing research into potassium channel modulators and gene therapies holds significant promise. Increased investment from pharmaceutical companies and research institutions focused on addressing the unmet needs of ATS patients is also contributing to market growth.

Key Market Drivers

Advancements in Genetic Diagnostics

The growth of the ATS market is strongly supported by progress in genetic diagnostics and electrophysiology, which have significantly enhanced the identification and understanding of this rare autosomal dominant condition. ATS is primarily caused by mutations affecting potassium ion channels, leading to characteristic symptoms including cardiac arrhythmias, muscle weakness, and distinct physical traits. With an estimated prevalence of 0.08 to 0.1 per 100,000 individuals, accurate diagnosis is essential.

Improvements in next-generation sequencing (NGS) and genetic screening techniques have enabled earlier and more precise detection, resulting in better disease management. Reports indicate that approximately 76% of physicians are utilizing genetic testing for rare diseases, reflecting a growing emphasis on early identification.

The integration of artificial intelligence (AI) into diagnostic workflows is accelerating the identification of rare mutations associated with ATS, facilitating tailored treatment strategies. Furthermore, the development of rare disease registries and patient databases is enriching the collective understanding of disease progression and treatment efficacy. Regulatory support for orphan drug development and accelerated approval pathways is also fostering innovation in therapy development for ATS.

Key Market Challenges

Diagnostic Delays Due to Complex Symptomatology

A primary challenge in the ATS market lies in diagnostic delays, driven by the condition's varied and often ambiguous symptom presentation. Patients may exhibit a broad range of clinical manifestations, including cardiac arrhythmias, episodes of muscle paralysis, and unique facial features-symptoms that, while indicative of ATS, are not exclusive to it.

This clinical variability frequently leads to misdiagnoses, as symptoms may be mistaken for more common cardiac or neuromuscular conditions. Consequently, patients often receive inappropriate treatments that fail to address the underlying genetic cause.

Furthermore, limited awareness of ATS among both the general public and healthcare professionals exacerbates diagnostic delays. Due to the rarity of the condition, physicians may not consider ATS early in the diagnostic process, resulting in prolonged patient journeys involving multiple specialists and extensive testing before a definitive diagnosis is reached.

These delays can be particularly detrimental in cases involving cardiac complications, where timely intervention is essential to prevent severe outcomes.

Key Market Trends

Cutting-Edge Genetic Diagnostics and Personalized Care

Technological advancements in genetic diagnostics-particularly next-generation sequencing (NGS) and whole exome sequencing (WES)-are revolutionizing the diagnosis and management of ATS. These techniques enable the rapid and accurate identification of pathogenic mutations, including those in the KCNJ2 and CACNA1S genes, which are commonly associated with ATS.

As a result, clinicians can now deliver faster, more accurate diagnoses, facilitating timely intervention and access to appropriate treatments. These developments have also deepened scientific understanding of ATS at the molecular level, allowing researchers to explore genotype-phenotype relationships and identify novel therapeutic targets.

This expanding knowledge base is supporting the development of more effective, genetically informed treatments and is accelerating progress toward personalized medicine approaches in the ATS space. Moreover, genetic diagnostics are increasingly being used for carrier screening among family members, enabling early detection, proactive monitoring, and preventative care-further driving demand for ATS-related medical services and diagnostics.

Key Market Players

  • Merck KGA.
  • Grevis Pharmaceuticals
  • Xeris Pharma
  • Novartis AG
  • Advanz Pharmaceuticals
  • Alembic Pharmaceuticals
  • Avet Pharmaceuticals
  • Hikma Pharmaceuticals
  • Micro Labs
  • Advagen Pharma

Report Scope:

In this report, the Global Andersen-Tawil Syndrome Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Andersen-Tawil Syndrome Market, By Disease Type:

  • Type 1
  • Type 2

Andersen-Tawil Syndrome Market, By Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Andersen-Tawil Syndrome Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Andersen-Tawil Syndrome Market.

Available Customizations:

Global Andersen-Tawil Syndrome Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Global Andersen-Tawil Syndrome Market Outlook

  • 4.1. Market Size & Forecast
    • 4.1.1. By Value
  • 4.2. Market Share & Forecast
    • 4.2.1. By Disease Type (Type 1, Type 2)
    • 4.2.2. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
    • 4.2.3. By Region
    • 4.2.4. By Company (2024)
  • 4.3. Market Map
    • 4.3.1. By Disease Type
    • 4.3.2. By Distribution Channel
    • 4.3.3. By Region

5. Asia Pacific Andersen-Tawil Syndrome Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Disease Type
    • 5.2.2. By Distribution Channel
    • 5.2.3. By Country
  • 5.3. Asia Pacific: Country Analysis
    • 5.3.1. China Andersen-Tawil Syndrome Market Outlook
      • 5.3.1.1. Market Size & Forecast
        • 5.3.1.1.1. By Value
      • 5.3.1.2. Market Share & Forecast
        • 5.3.1.2.1. By Disease Type
        • 5.3.1.2.2. By Distribution Channel
    • 5.3.2. India Andersen-Tawil Syndrome Market Outlook
      • 5.3.2.1. Market Size & Forecast
        • 5.3.2.1.1. By Value
      • 5.3.2.2. Market Share & Forecast
        • 5.3.2.2.1. By Disease Type
        • 5.3.2.2.2. By Distribution Channel
    • 5.3.3. Australia Andersen-Tawil Syndrome Market Outlook
      • 5.3.3.1. Market Size & Forecast
        • 5.3.3.1.1. By Value
      • 5.3.3.2. Market Share & Forecast
        • 5.3.3.2.1. By Disease Type
        • 5.3.3.2.2. By Distribution Channel
    • 5.3.4. Japan Andersen-Tawil Syndrome Market Outlook
      • 5.3.4.1. Market Size & Forecast
        • 5.3.4.1.1. By Value
      • 5.3.4.2. Market Share & Forecast
        • 5.3.4.2.1. By Disease Type
        • 5.3.4.2.2. By Distribution Channel
    • 5.3.5. South Korea Andersen-Tawil Syndrome Market Outlook
      • 5.3.5.1. Market Size & Forecast
        • 5.3.5.1.1. By Value
      • 5.3.5.2. Market Share & Forecast
        • 5.3.5.2.1. By Disease Type
        • 5.3.5.2.2. By Distribution Channel

6. Europe Andersen-Tawil Syndrome Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Disease Type
    • 6.2.2. By Distribution Channel
    • 6.2.3. By Country
  • 6.3. Europe: Country Analysis
    • 6.3.1. France Andersen-Tawil Syndrome Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Disease Type
        • 6.3.1.2.2. By Distribution Channel
    • 6.3.2. Germany Andersen-Tawil Syndrome Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Disease Type
        • 6.3.2.2.2. By Distribution Channel
    • 6.3.3. Spain Andersen-Tawil Syndrome Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Disease Type
        • 6.3.3.2.2. By Distribution Channel
    • 6.3.4. Italy Andersen-Tawil Syndrome Market Outlook
      • 6.3.4.1. Market Size & Forecast
        • 6.3.4.1.1. By Value
      • 6.3.4.2. Market Share & Forecast
        • 6.3.4.2.1. By Disease Type
        • 6.3.4.2.2. By Distribution Channel
    • 6.3.5. United Kingdom Andersen-Tawil Syndrome Market Outlook
      • 6.3.5.1. Market Size & Forecast
        • 6.3.5.1.1. By Value
      • 6.3.5.2. Market Share & Forecast
        • 6.3.5.2.1. By Disease Type
        • 6.3.5.2.2. By Distribution Channel

7. North America Andersen-Tawil Syndrome Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Disease Type
    • 7.2.2. By Distribution Channel
    • 7.2.3. By Country
  • 7.3. North America: Country Analysis
    • 7.3.1. United States Andersen-Tawil Syndrome Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Disease Type
        • 7.3.1.2.2. By Distribution Channel
    • 7.3.2. Mexico Andersen-Tawil Syndrome Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Disease Type
        • 7.3.2.2.2. By Distribution Channel
    • 7.3.3. Canada Andersen-Tawil Syndrome Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Disease Type
        • 7.3.3.2.2. By Distribution Channel

8. South America Andersen-Tawil Syndrome Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Disease Type
    • 8.2.2. By Distribution Channel
    • 8.2.3. By Country
  • 8.3. South America: Country Analysis
    • 8.3.1. Brazil Andersen-Tawil Syndrome Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Disease Type
        • 8.3.1.2.2. By Distribution Channel
    • 8.3.2. Argentina Andersen-Tawil Syndrome Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Disease Type
        • 8.3.2.2.2. By Distribution Channel
    • 8.3.3. Colombia Andersen-Tawil Syndrome Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Disease Type
        • 8.3.3.2.2. By Distribution Channel

9. Middle East and Africa Andersen-Tawil Syndrome Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Disease Type
    • 9.2.2. By Distribution Channel
    • 9.2.3. By Country
  • 9.3. MEA: Country Analysis
    • 9.3.1. South Africa Andersen-Tawil Syndrome Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Disease Type
        • 9.3.1.2.2. By Distribution Channel
    • 9.3.2. Saudi Arabia Andersen-Tawil Syndrome Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Disease Type
        • 9.3.2.2.2. By Distribution Channel
    • 9.3.3. UAE Andersen-Tawil Syndrome Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Disease Type
        • 9.3.3.2.2. By Distribution Channel

10. Market Dynamics

  • 10.1. Drivers
  • 10.2. Challenges

11. Market Trends & Developments

  • 11.1. Recent Developments
  • 11.2. Product Launches
  • 11.3. Mergers & Acquisitions

12. Global Andersen-Tawil Syndrome Market: SWOT Analysis

13. Porter's Five Forces Analysis

  • 13.1. Competition in the Industry
  • 13.2. Potential of New Entrants
  • 13.3. Power of Suppliers
  • 13.4. Power of Customers
  • 13.5. Threat of Substitute Product

14. Competitive Landscape

  • 14.1. Merck KGA.
    • 14.1.1. Business Overview
    • 14.1.2. Company Snapshot
    • 14.1.3. Products & Services
    • 14.1.4. Current Capacity Analysis
    • 14.1.5. Financials (In case of listed)
    • 14.1.6. Recent Developments
    • 14.1.7. SWOT Analysis
  • 14.2. Grevis Pharmaceuticals
  • 14.3. Xeris Pharma
  • 14.4. Novartis AG
  • 14.5. Advanz Pharmaceuticals
  • 14.6. Alembic Pharmaceuticals
  • 14.7. Avet Pharmaceuticals
  • 14.8. Hikma Pharmaceuticals
  • 14.9. Micro Labs
  • 14.10. Advagen Pharma

15. Strategic Recommendations

16. About Us & Disclaimer